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Abstract  
BACKGROUND: Porokeratosis is characterised by one or more atrophic patches surrounded by a distinctive 
peripheral keratotic ridge, typically found on sun-exposed areas, with several clinical variants and typical 
histological findings. Despite ultraviolet radiation, varies antibody - related autoimmune disease treated with 
systemic steroids and other immunosuppressive conditions such as chronic liver disease, HIV and organ 
transplantations have been implicated in its etiopathology. 
CASE REPORT: We present a case of porokeratosis, associated with idiopathic thrombocytopenia in 74 - year 
old, otherwise healthy male patient, as we discuss the previously reported associated disorders. 
CONCLUSION: Regarding all of the polymorphism of clinical presentation, associated disorders and treatment 
responses, we could conclude that disseminated porokeratosis is still an unknown well disorder, which will 
continue to surprise the physicians in future. The screening and follow up of the patients is mandatory in all cases 
because as we see, porokeratosis has multiple unexpected faces, which require circumstantial clinical and 
paraclinical behaviour. 
 
 
 
 
 
 
 
Introduction 
 
Porokeratosis represents a clonal disorder of 
keratinisation, first described in 1983 as a chronic 
parakeratotic skin disorder [1]. The condition is 
characterised by one or more atrophic patches, 
typically found on sun-exposed areas, surrounded by 
a distinctive peripheral keratotic ridge, called the 
cornoid lamella [1][2]. Several clinical variants have 
been described, as the most common among them 
include classic porokeratosis of Mibelli (PM), 
disseminated superficial actinic porokeratosis (DSAP) 
and its nonactinic variant disseminated superficial 
porokeratosis (DSP), linear porokeratosis, 
porokeratosis palmaris et plantaris disseminata 
(PPPD), punctate porokeratosis, which might 
represent a variant of PPPD [1][2][3]. 
Much less commonly reported clinical 
subtypes include porokeratosis ptychotropica (a 
verrucous variant localised in the gluteal region) [3], 
porokeratoma, also referred to as porokeratotic 
acanthoma [4], porokeratotic adnexal ostial nevus 
(PAON) - a rare congenital disorder of keratinization 
with eccrine and hair follicle involvement [5]. Although 
aetiology is not well - established, exposure to 
ultraviolet radiation, organ transplantation, 
chemotherapy, repetitive trauma, liver failure, chronic 
renal failure, hepatitis C, HIV, and other diseases 
associated with immunosuppression are considered 
risk factors which activate abnormal clones of 
keratinocytes [3]. Gene mutations in mevalonate 
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pathway enzymes have also been implicated in 
etiopathology, such as mevalonate kinase (MVK), 
phosphomevalonate kinase (PMVK), mevalonate 
decarboxylase (MVD), and farnesyl diphosphate 
synthase (FDPS), as c.746 T > C and c.875A > G of 
the MVD gene are most common mutations [1][6]. 
Beside the immunosuppression variety of disorders 
associated with the condition, disseminated superficial 
porokeratosis has been reported in systemic lupus 
erythematosus (SLE) patient with long-term 
corticosteroid treatment [7], patients with diabetes 
mellitus [8] and associated with haematological 
disorders such as Hodgkin's disease and B-cell 
lymphoma [9]. 
Here we present a patient with disseminated 
porokeratosis, associated with idiopathic 
thrombocytopenia. To the best of our knowledge, this 
is the first report of disseminated superficial 
porokeratosis, associated with idiopathic 
thrombocytopenia. 
 
 
Case report 
 
A 74 – year - old male patient presented with 
2 - months history of erythematous rash on the lower 
legs, accompanied by itching. The clinical examination 
revealed multiple individual erythematous, slightly 
atrophic macules and papules, with brownish 
discolouration, surrounded by peripheral keratotic 
ridge, resembling cornoid lamella, disseminated on 
the chest, back and lower extremities (Fig. 1 a, b, c, 
d). 
 
Figure 1: a, b – Clinical presentation of disseminated porokeratosis 
on chest and back in 74-year-old male patient; c, d – Clinical 
presentation of disseminated porokeratosis on lower legs, with 
closer view of cornoid lamella 
Multiple excoriations and linear defects, from 
scratching, were also established. The conducted 
paraclinical blood examinations revealed decreased 
plated cells count (107.0 10^9/l) and increased 
cholesterol (8.4 mmol/l: HDL - 2.43, LDL - 5.33 
mmol/l). The performed imaging diagnostic screening 
did not reveal organ pathologies. The 
histopathological examination after performed 
biopsies obtained focal absence of the granular layer, 
dyskeratotic cells observed in the subjacent upper 
spinous layer.  
A mild lymphocytic infiltrate were seen around 
an increased number of capillaries in the underlying 
dermis. 
Dermis showed a non-specific inflammatory 
cell infiltrate. Epithelium deep to the tier was 
vacuolated and devoid of a granular cell layer (Fig. 2 
a, b). Dyskeratotic cells were observed in the 
subjacent upper spinous layer (Fig. 2 c). Keratin-filled 
epidermal invagination with an angulated, 
parakeratotic tier (cornoid lamella) (Fig. 2 d).  
 
Figure 2: Histological findings; a, b - Focal absence of the granular 
layer, dyskeratotic cells observed in the subjacent upper spinous 
layer. A mild lymphocytic infiltrate were seen around an increased 
number of capillaries in the underlying dermis. Dermis showed a 
non-specific inflammatory cell infiltrate. Epithelium deep to the tier 
was vacuolated and devoid of a granular cell layer; c - Dyskeratotic 
cells were observed in the subjacent upper spinous layer; d - 
Keratin-filled epidermal invagination with an angulated, 
parakeratotic tier (cornoid lamella) 
 
The diagnosis of disseminated superficial 
porokeratosis, associated with idiopathic 
thrombocytopenia was made, based on the clinical 
examination, laboratory and histological findings. A 
systemic administration of acitretin 10 mg was 
initiated with local application of vitamin D3 analogue 
(calcipotriol) and corticosteroid (betamethasone), 
combined in one commercial product as a gel, without 
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a satisfactory therapeutic response within the 
following two weeks. Cryotherapy was initiated in 
combination with systemic acitretin and calcipotriol, 
combined with a corticosteroid. Regarding the 
thrombocytopenia, the dose of acitretin was not 
increased. The satisfactory therapeutic response was 
achieved in one month.  
 
 
Discussion 
 
Porokeratosis is considered as an autosomal 
dominant inherited disorder with the variable clinical 
presentation, but unified histological characteristics of 
cornoid lamella [1][2]. The approximate age of onset is 
45 - 50 years, although the reported cases range 
between 27 - 84 years [1][2]. Although it is believed 
that the sun-exposed areas are mainly affected, the 
most common regions of occurrence are extremities, 
the buttocks, and genitogluteal region, while facial 
lesions are rare [2][4]. It is believed that ultraviolet 
radiation is the triggering factors in genetically 
predisposed individuals [2]. On the other hand, 
various antibody-related autoimmune diseases treated 
with systemic steroids and other immunosuppressive 
conditions such as chronic liver disease, HIV and 
organ transplantations have also been implicated in its 
etiopathology [11]. Despite that, our literature review 
established cases of association between 
disseminated porokeratosis and pyoderma 
gangrenosum [10], a case of dermatomyositis [12], 
scleroderma [13], Sjogren syndrome [14] and 
rheumatoid arthritis [15]. Authors suggest that 
immunosuppressant therapy is the reason for the 
occurrence of the porokeratosis [10][11]. Although 
disseminated superficial porokeratosis has rarely 
been reported in association with internal malignancy, 
its occurrence in patients with hepatitis C virus-related 
hepatocellular carcinoma, cholangiocarcinoma, and 
ovarian cancer suggests a paraneoplastic nature of 
the cutaneous disease [16]. Furthermore, 
porokeratotic lesions can give raise of bowenoid 
lesions and squamous cell carcinoma as 
precancerosis trigger with aggressive behaviour and 
poor prognosis [17]. A porokeratotic lesion, showing 
histological changes during his disease, including 
cellular atypia, dysplasia, and invasive squamous cell 
carcinoma is known as “malignant superficial 
porokeratosis” [18]. Sporadic case reports in the 
literature represents porokeratosis in patient with 
polycythemia rubra vera [19], pseudoxanthoma 
elasticum [20], multiple myeloma [21] and 
myelodysplastic syndrome [22][23]. Although rare, 
benzylhydrochlorothiazide - induced porokeratotic 
lesions in stable porokeratosis of Mibelli accompanied 
by eosinophilic spongiosis have also been reported 
[24]. 
Although hematologic disorders are not 
uncommonly accompanied by disseminated 
porokeratosis, we couldn’t find a case of porokeratosis 
associated with idiopathic thrombocytopenia (as in the 
presented case) within our thorough literature revue, 
encompassing the available reported cases between 
1984 and present date. Although various treatment 
options have been implicated with various degrees of 
success, including topical diclofenac, vitamin D 3 
analogs, 5-fluorouracil, retinoids, 5% imiquimod, 
photodynamic therapy, carbon dioxide laser and oral 
retinoids, therapy with good response is rather poor 
[1][2]. Reports of disseminated superficial actinic 
porokeratosis treated with vitamin D 3 analogs are 
rare in general; with no satisfactory enough effect 
obtained with calcipotriol monotherapy [25][26]. 
Simultaneous application of vitamin D3 analog 
(calcipotriol) and corticosteroid (betamethasone), 
combined in a one commercial product as a gel is 
reported as a promising, more effective new entity, 
because of the simultaneous synergetic effects of the 
substations, which normalize the proliferation of the 
keratinocytes by calcipotriol on one hand, and the 
reducing of the inflammation by the corticosteroid, on 
another [27]. 
Considering the polymorphism of clinical 
presentation, the variety of associated disorders and 
the differences in the treatment responses, we could 
conclude that disseminated porokeratosis is still an 
unknown well disorder, which will continue to surprise 
the physicians in future. The screening and follow up 
of the patients is mandatory in all cases because as 
we see, porokeratosis has multiple unexpected faces, 
which require circumstantial clinical and paraclinical 
behaviour. 
 
 
References 
1. Sun RF, Chen H, Zhu W, Lian S. Dermoscopic Features and 
Gene Mutation in the Mevalonate Pathway of Five Sporadic 
Patients with Porokeratosis. Chin Med J. 2017; 130:1747-8. 
https://doi.org/10.4103/0366-6999.209905 PMid:28685731 
PMCid:PMC5520568 
2. Anderson I1, Routt ET2, Jim On SC. Disseminated superficial 
actinic porokeratosis treated with ingenol mebutate gel 0.05. Cutis. 
2017; 99(3):E36-E39. PMid:28398427  
 
3. Tebet AC, Oliveira TG, Oliveira AR, Moriya FS, Oliveira J Filho, 
Cucé LC. Porokeratosis ptychotropica. An Bras Dermatol. 2016; 
91(5 suppl 1):134-136. https://doi.org/10.1590/abd1806-
4841.20164399 PMid:28300921 PMCid:PMC5325020 
 
4. Walsh SN, Hurt MA, Santa Cruz DJ. Porokeratoma. Am J Surg 
Pathol. 2007; 31(12):1897-901. 
https://doi.org/10.1097/PAS.0b013e31806910c7 PMid:18043046  
 
5. Llamas-Velasco M, Hilty N, Kempf W. Porokeratotic adnexal 
ostial naevus: review on the entity and therapeutic approach. J Eur 
Acad Dermatol Venereol. 2015; 29(10):2032-7. 
https://doi.org/10.1111/jdv.12732 PMid:25255914  
 
6. Li X, Zhou Q, Zhu L, Zhao Z, Wang P, Zhang L, Zhang G, Wang 
X. Analysis of clinical and genetic features of nine patients with 
disseminated superfacial actinic porokeratosis. Zhonghua Yi Xue 
Yi Chuan Xue Za Zhi. 2017; 34(4):481-485. PMid:28777842  
 
7. Robak E, Wozniacka A, Sysa-Jedrezejowska A, Biernat W, 
 
Case Report 
_______________________________________________________________________________________________________________________________ 
 
_______________________________________________________________________________________________________________________________ 
142                                                                                                                                                                                                https://www.id-press.eu/mjms/index 
 
 
Robak T. Disseminated superficial actinic porokeratosis in a patient 
with systemic lupus erythematosus. Br J Dermatol. 1999; 141:759 
– 761. https://doi.org/10.1046/j.1365-2133.1999.03134.x 
PMid:10583141  
8. Nakamura M, Fukamachi S, Tokura Y. Acute onset 
disseminated superficial porokeratosis associated with 
exacerbation of diabetes mellitus due to development of anti-insulin 
antibodies. Dermatoendocrinol. 2010; 2(1):17-8. 
https://doi.org/10.4161/derm.2.1.11816 PMid:21547143 
PMCid:PMC3084960 
 
9. Diluvio L, Campione E, Paterno EJ, et al. Acute onset 
disseminated superficial porokeratosis heralding diffuse large B-
cell lymphoma. Eur J Dermatol. 2008; 18:349 – 350. 
PMid:18474476  
 
10. di Meo N, Fluehler C, Perkan V, Trevisan G. Disseminated 
superficial porokeratosis and pyoderma gangrenosum. Dermatol 
Online J. 2010; 16(10):15. PMid:21062609  
 
11. Mundi JP, Cerullo L, Cotliar J. Porokeratosis in a patient with 
hepatitis of unclear etiology. J Drugs Dermatol. 2010; 9(3):258-60. 
PMid:20232588  
 
12. Monteagudo-Sánchez B, Ginarte M, Durana C, Labandeira J, 
de las Heras C, Cacharrón JM. Porokeratosis in a patient with 
dermatomyositis. Actas Dermosifiliogr. 2006; 97(10):650-2. 
https://doi.org/10.1016/S0001-7310(06)73487-1 
 
13. Kluger N, Guilpain P, Leclerc-Mercier S, Emilie S, Guillevin L, 
Mouthon L. Superficial porokeratosis of the lower limbs during 
systemic scleroderma Presse Med. 2009; 38(1):146-8. 
https://doi.org/10.1016/j.lpm.2008.06.023 PMid:18990541  
 
14. Terranova M, Amato L, Massi D, Fabbri P. Disseminated 
superficial actinic porokeratosis in a patient with Sjögren syndrome. 
Skinmed. 2003; 2(6):390-1. https://doi.org/10.1111/j.1540-
9740.2003.02261.x PMid:14673257  
 
15. Jung JY, Yeon JH, Ryu HS, Youn SW, Park KC, Huh CH. 
Disseminated superficial porokeratosis developed by 
immunosuppression due to rheumatoid arthritis treatment. J 
Dermatol. 2009; 36(8):466-7. https://doi.org/10.1111/j.1346-
8138.2009.00678.x PMid:19691753  
 
16. Cannavó SP, Borgia F, Adamo B, Guarneri B. Simultaneous 
development and parallel course of disseminated superficial 
porokeratosis and ovarian cancer: Coincidental association or true 
paraneoplastic syndrome? J Am Acad Dermatol. 2008; 58(4):657-
60. https://doi.org/10.1016/j.jaad.2007.12.030 PMid:18258333  
 
17. Rongioletti F1, Rebora A. Disseminated porokeratosis with fatal 
metastatic squamous cell carcinoma: an additional case of 
"malignant disseminated porokeratosis". Am J Dermatopathol. 
2002; 24(2):144-8. https://doi.org/10.1097/00000372-200204000-
 
00007 
18. Brodkin RH, Rickert RR, Fuller FW, Saporito C. Malignant 
disseminated porokeratosis. Arch Dermatol. 1987; 123(11):1521-6. 
https://doi.org/10.1001/archderm.1987.01660350121027 
PMid:3674910  
 
19. Kanitakis J, Arbona-Vidal E, Faure M. Porokeratosis in patients 
with polycythemia rubra vera: a new side effect of hydroxyurea? J 
Eur Acad Dermatol Venereol. 2012; 26(8):1040-1. 
https://doi.org/10.1111/j.1468-3083.2011.04202.x PMid:21812837  
 
20. Torchia D, Romanelli P, Schachner LA. Disseminated 
superficial actinic porokeratosis associated with pseudoxanthoma 
elasticum. Eur J Dermatol. 2011; 21(4):600-1. PMid:21616751  
 
21. Benmously Mlika R, Kenani N, Badri T, Ben Romdhane S, 
Debbiche A, Souissi A, Ben Ayed M, Mokhtar I, Fenniche S. 
Localized genital porokeratosis in a female patient with multiple 
myeloma. J Eur Acad Dermatol Venereol. 2009; 23(5):584-5. 
https://doi.org/10.1111/j.1468-3083.2008.02967.x PMid:18759788  
 
22. Luelmo-Aguilar J, Gonzalez-Castro U, Mieras-Barcelo C, 
Castells-Rodellas A. Disseminated porokeratosis and 
myelodysplastic syndrome. Dermatology. 1992; 184(4):289. 
https://doi.org/10.1159/000247571 PMid:1498397  
 
23. Levin RM, Heymann WR. Superficial disseminate porokeratosis 
in a patient with myelodysplastic syndrome. Int J Dermatol. 1999; 
38(2):138-9. https://doi.org/10.1046/j.1365-4362.1999.00504.x 
 
24. Inamoto N, Watanabe T, Nakamura K. Porokeratosis of Mibelli: 
benzylhydrochlorothiazide-induced new lesions accompanied by 
eosinophilic spongiosis. J Am Acad Dermatol. 1984; 11(2 Pt 
2):357-61. https://doi.org/10.1016/S0190-9622(84)70172-1 
 
25. Nakamura Y, Yamaguchi M, Nakamura A, Muto M. Calcipotriol 
and adapalene therapy for disseminated superficial actinic 
porokeratosis. Indian J Dermatol Venereol Leprol. 2014; 80:373-4. 
https://doi.org/10.4103/0378-6323.136981 PMid:25035379  
 
26. Böhm M, Luger TA, Bonsmann G. Disseminated superficial 
actinic porokeratosis: treatment with topical tacalcitol. J Am Acad 
Dermatol. 1999; 40(3):479-80. https://doi.org/10.1016/S0190-
9622(99)70502-5 
 
27. Tchernev G, Chokoeva AA, Ivanova B, Mangarov H, Vidolova 
NG. Disseminated superficial actinic porokeratosis (DSAP): 
significant improvement after local administration of 
calcipotriol/betamethasone gel? Wien Med Wochenschr. 2017; 
167(3-4):85-88. https://doi.org/10.1007/s10354-016-0484-8 
PMid:27468973  
 
 
